This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
External Descriptors
Not available
1. Djoumbou Feunang Y, Eisner R, Knox C, Chepelev L, Hastings J, Owen G, Fahy E, Steinbeck C, Subramanian S, Bolton E, Greiner R, and Wishart DS. ClassyFire: Automated Chemical Classification With A Comprehensive, Computable Taxonomy. Journal of Cheminformatics, 2016, 8:61.
Certificats (CoA, COO, BSE/TSE et tableau d'analyse)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Propriétés chimiques et physiques
Poids moléculaire
426.500 g/mol
XLogP3
3.000
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
5
Rotatable Bond Count
6
Exact Mass
426.192 Da
Monoisotopic Mass
426.192 Da
Topological Polar Surface Area
112.000 Ų
Heavy Atom Count
32
Formal Charge
0
Complexity
813.000
Isotope Atom Count
0
Defined Atom Stereocenter Count
0
Undefined Atom Stereocenter Count
0
Defined Bond Stereocenter Count
0
Undefined Bond Stereocenter Count
0
The total count of all stereochemical bonds
0
Covalently-Bonded Unit Count
1
Calculateurs de solution
Molarity Calculator
Determine the necessary mass, volume, or concentration for preparing a solution.
Dilution Calculator
Determine the dilution needed to prepare a stock solution.
Reconstitution Calculator
Avis
Avis des clients
Application Protocols
No manufacturer-validated application protocols are provided for this product.
Provided data
Tested applications (e.g., WB, IHC, IF, FC), recommended dilutions, positive controls: Not specified for this item; refer to CoA/Spec Sheet.
General usage examples (for small-molecule standards)
Stock preparation: Dissolve to 10–50 mM in dry DMSO; aliquot and store protected from light. Verify concentration by UV or quantitative NMR if accuracy is critical.
Biochemical assay dosing: Serially dilute stock in assay buffer keeping final DMSO ≤0.5–1% v/v; include vehicle control.
LC–MS method development: Start with C18, water/acetonitrile (0.1% formic acid or ammonium formate); scan 200–400 nm for UV and explore ESI±. Adjust gradient to resolve from related impurities.
Note
These are general suggestions for handling hydrophobic small molecules, not validated protocols for Ripisartan specifically.
Biological Roles
Biochemical/physiological context is provided for scientific background only. This product is for research use only and not for human or veterinary applications.
Literature overview (nonclinical)
Ripisartan is described in the literature as a small-molecule angiotensin II type 1 (AT1) receptor antagonist within the “sartan” class. Such compounds are used as tool molecules to probe the renin–angiotensin system (RAS) in biochemical and cellular models.
Mechanistic notes (general to AT1 antagonists)
AT1 receptors are GPCRs; antagonists typically bind the orthosteric pocket, blocking AngII-mediated Gq/11 signaling, downstream IP3/Ca2+ mobilization, and MAPK activation. Antagonism can be assessed by displacement binding (radioligand or fluorescent) and functional readouts (e.g., calcium flux, reporter assays).
Experimental utility
Enables delineation of AT1 vs AT2 receptor contributions using selective ligands and antagonists in parallel.
Supports pathway mapping of angiotensinogen–renin–ACE–AngII–AT1/AT2 axes in vitro.
Cautions
Receptor selectivity, potency, and functional bias for Ripisartan should be confirmed from primary sources before assuming equivalency with other sartans; no potency/selectivity data are provided here.
Avoid extrapolating in vitro observations to clinical contexts; adhere strictly to research-use-only limitations.
Buffer Applications
This product is a hydrophobic small molecule standard and is not a buffering agent. Accordingly, classic buffer-system recipes (phosphate, Tris, HEPES, etc.) are not applicable.
Practical guidance
If dosing into aqueous buffers for assays, prepare concentrated stocks in DMSO or DMF and dilute into the target buffer while maintaining a low final organic content (typically ≤0.5–1% v/v).
To enhance apparent solubility, consider including a small amount of co-solvent or a nonionic surfactant (e.g., 0.01–0.1% Tween 80 or Pluronic), after confirming assay compatibility.
Adjust buffer pH based on the ionization of the compound (if acidic/basic groups are present) to maintain solubility and consistent exposure; item-specific pKa values are not provided here.
Green Alternatives
Because this product is a target compound rather than a solvent or reagent class, “green alternatives” primarily concern solvent and workflow choices when handling Ripisartan solutions. Item-specific green metrics are not provided.
Greener solvent choices (general guidance)
Prefer acetonitrile or ethanol over chlorinated solvents where feasible.
Consider 2‑MeTHF or ethyl acetate for nonaqueous preparation/partitioning steps if solubility allows.
Use water-rich mobile phases (HILIC or mixed-mode) for LC where compatible with analyte retention.
Comparison (general; select cases)
DCM/CHCl3 vs 2‑MeTHF/EtOAc: lower toxicity and better sustainability for the latter, but solubility of hydrophobic aromatics may be lower; evaporative removal is easier for EtOAc than for NMP/DMF.
Process considerations
Minimize DMSO carryover in biological assays by preparing more concentrated stocks and smaller spike volumes.
Employ miniaturized assays and closed-vial workflows to reduce solvent use and emissions.
Validate room-temperature dissolution/filtration to avoid unnecessary heating.
Waste
Segregate halogenated from non-halogenated organic waste; capture DMSO/DMF waste separately per local policy.
Pharmaceutical Uses
No pharmacopeial status or excipient role is provided for this catalog item. The information below pertains to research and analytical use; no therapeutic or clinical claims are made.
Research/manufacturing context (general)
Reference standard: Useful for analytical method development, system suitability, and stability-indicating methods when studying related chemical space.
Impurity profiling: May serve as a comparator or spiking standard in forced-degradation and impurity-mapping studies.
Calibration/quantitation: Preparation of calibration curves for LC–UV/LC–MS.
Regulatory notes
If used in GMP or GLP settings, establish full chain-of-custody and method validation per ICH Q2/Q14. Obtain and archive the lot-specific CoA, SDS, and any spectral data.
Not provided for this item
No information on USP/EP monographs, compendial designation, or excipient functionality.
Formulation R&D (general)
For preformulation research, evaluate solubility in biorelevant media and partition behavior; consider salt formation or amorphous dispersions if pursuing exploratory delivery science. These activities are outside the scope of this catalog listing and must comply with research-only restrictions.
Physical Properties
Item-specific physical constants were not provided. Do not derive specifications from secondary sources; verify on CoA/Spec Sheet for release-critical work.
Item-specific values
Appearance: Not specified for this item; refer to CoA/Spec Sheet.
Melting point: Not specified for this item; refer to CoA/Spec Sheet.
Boiling point: Not applicable/rarely reported for high-MW drug-like solids; Not specified for this item; refer to CoA/Spec Sheet.
Density: Not specified for this item; refer to CoA/Spec Sheet.
Solubility (water/organics): Not specified for this item; refer to CoA/Spec Sheet.
LogP/logD, pKa, refractive index, UV cutoff: Not specified for this item; refer to CoA/Spec Sheet.
Literature/general expectations for sartan-like chemotypes (for planning only; not item specifications)
Physical state: Typically a crystalline solid with low aqueous solubility.
Acidity: Tetrazole-containing sartans often have an acidic pKa ~4–5 (literature) for the tetrazole proton, giving weakly acidic behavior and improved receptor binding; actual pKa must be confirmed for Ripisartan specifically.
Solubility handling: Many drug-like aromatics dissolve in high-boiling polar aprotic solvents (DMSO, DMF, NMP) and in chlorinated/aromatic solvents; aqueous solubility may require co-solvents or salt formation.
Practical notes
For quantitative work (LC/UV, LC–MS), determine λmax and extinction coefficient experimentally for your batch; no UV data are provided here.
Hygroscopicity/polymorph tendencies are unknown for this item—evaluate under your lab conditions if critical to your application.
Quality and Grades
Item-specific quality information
Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.
Stabilizers/Inhibitors: Not specified for this item; refer to CoA/Spec Sheet.
What the grade typically implies (general guidance)
For small-molecule screening standards, grades often indicate analytical suitability (e.g., ≥95–98% purity by HPLC/LC–MS), tight control of identity (NMR/HRMS), and limited residual solvents/metals. In the absence of a declared grade, verify fitness-for-use with your internal acceptance criteria.
Recommended quality checks upon receipt (best practices)
Identity: 1H NMR and LC–MS against reference data (CAS 148504-51-2, CID 132840). Consider 13C NMR for structural confirmation.
Purity: HPLC or UPLC with photodiode array; include orthogonal method if critical (e.g., GC for volatile impurities).
Water/residual solvents: Karl Fischer/GC–MS as applicable. Item-specific limits are not provided here.
Solid-state: If performance is polymorph-dependent, record PXRD/DSC/TGA and document lot-to-lot consistency.
Trace specifications
Water content, peroxides, metal limits, and UV cutoff are Not specified for this item; refer to CoA/Spec Sheet. Do not assume unstated limits.
Reaction and Applications
This product is provided as a finished small molecule for research use; it is not primarily intended as a synthetic reagent. Accordingly, “reaction” applications are limited. The following focuses on practical research uses and handling.
Typical research applications (general)
Reference standard: Method development/validation for LC–UV/LC–MS, retention-time locking, system suitability in impurity profiling of related chemical space.
Screening compound: Tool compound in biochemical or cell-based assays investigating the renin–angiotensin pathway (see Biological Roles). Ensure appropriate negative/positive controls.
Practical handling tips
Prepare DMSO stocks under dry conditions; aliquot to avoid repeated freeze–thaw of solutions.
Assess light/air stability by short stress tests (ambient light/air, 24–48 h) prior to long assays.
For quantitative work, establish response factors and extinction coefficients under your method conditions.
If using in derivatization or conjugation (advanced; general)
Sartans bearing acidic tetrazoles/carboxylates can, in principle, form salts or be temporarily protected for conjugation studies. Such transformations are application-specific and not typical for catalog use of a screening standard.
Not provided for this item
There are no manufacturer-stated named-reaction uses or catalyst applications for this product in the provided data.
Reaction Conditions
No manufacturer-recommended reaction conditions are applicable, as this product is not sold as a reagent. For laboratories conducting independent research with the compound (e.g., assay dosing or analytical chemistry), consider the following general conditions for solution handling and analysis.
Solution preparation (general)
Dissolve in dry DMSO or DMF to prepare 10–50 mM stocks; sonication and mild warming (≤40 °C) can aid dissolution.
For LC analyses, dilute into acetonitrile/water with 0.1% formic acid or ammonium formate, depending on desired ionization mode; verify stability.
Stability screening (general)
Perform short-term stress tests: neutral, acidic, and basic aqueous media; oxidative (H2O2, low %) and thermal (40–60 °C) to map degradation pathways. Item-specific stability data are not provided.
Strong UV absorption from aromatic rings; LC–MS typically practicable in both ESI+ and ESI− if an acidic group is present. Optimize cone voltage and source temperature empirically.
Not provided for this item
No specific reaction temperature, catalysts, or synthetic yields are claimed or recommended for this product.
Safety and Handling
Always consult the product SDS for authoritative hazard classification and response procedures. The following summarizes provided data and general best practices for small-molecule research chemicals.
Item-specific hazard information (from Product Data)
Signal word: Not specified for this item; refer to SDS.
H-statements: Not specified for this item; refer to SDS.
GHS classification: Not specified for this item; refer to SDS.
Pictograms: Not specified for this item; refer to SDS.
General laboratory precautions (good practice)
PPE: Safety glasses, lab coat, and appropriate chemically resistant gloves; add splash protection/respiratory protection if dust/aerosol may form.
Engineering controls: Handle powders in a fume hood or ventilated enclosure to minimize inhalation exposure.
Hygiene: Avoid inhalation of dust, ingestion, and skin/eye contact. Wash thoroughly after handling.
Handling and incompatibilities (general)
Store tightly closed, away from strong oxidizers and strong acids/bases unless compatibility is verified.
Avoid generation of dust and static discharge; ground equipment during weigh-outs if large quantities are handled.
First-aid overview (general)
Inhalation: Move to fresh air; seek medical attention if symptoms persist.
Skin/eye contact: Rinse with water for at least 15 minutes; remove contaminated clothing; seek medical advice if irritation continues.
Ingestion: Rinse mouth; do not induce vomiting; seek medical attention.
Waste disposal
Dispose of in accordance with institutional and local regulations for organic research chemicals; incineration via a licensed contractor is typical.
Solvent Selection
Item-specific solubility data are not provided. The following guidance reflects common behavior of lipophilic, aromatic small molecules used as screening standards; confirm empirically for Ripisartan.
General solvent compatibility (literature/general)
Likely good solvents: DMSO, DMF, NMP; often soluble in dichloromethane and acetonitrile; variable in methanol/ethanol depending on ionization state.
Water: Typically low intrinsic solubility unless ionized (e.g., as a salt) or formulated with co-solvents/surfactants.
Polarity/dielectric considerations (general)
Polar aprotic solvents (high dielectric) support dissolution of heteroatom-rich aromatics and provide LC–MS compatibility.
For aqueous assays, prepare a concentrated DMSO stock (e.g., 10–50 mM), then dilute into buffer keeping final DMSO ≤0.5–1% v/v to minimize biological assay artifacts.
Comparison to alternative media (general)
Where chlorinated solvents are discouraged, consider acetonitrile or 2-MeTHF if solubility permits; confirm stability and recovery.
Practical tips
Warm gently (≤40 °C) and sonicate to aid dissolution; avoid prolonged heating.
Filter 0.2 µm for analytical use; verify no analyte loss to membrane (PTFE/PP often preferred for hydrophobic compounds).
Monitor for precipitation after dilution into aqueous buffers; include co-solvent or surfactant as needed.
Storage and Reconstitution
Item-specific storage/shipping
Storage conditions: Room temperature (per Product Data). Maintain in a tightly closed container, desiccated if possible, and protected from light.
Shipped in: Not specified for this item; refer to CoA/Spec Sheet.
Reconstitution (general guidance; not item-specific specifications)
Prepare concentrated stocks in anhydrous DMSO or DMF. Aim for 10–50 mM to minimize final co‑solvent in assays.
Mix by gentle vortexing/sonication; avoid strong heating. If needed, warm to ≤40 °C briefly to aid dissolution.
Filter through 0.2 µm PTFE prior to analytical use to remove particulates. Confirm no adsorption losses.
Solution stability (general)
Store aliquoted solutions at −20 to −80 °C to reduce degradation and avoid repeated freeze–thaw. Protect from light.
Establish stability-indicating methods (LC–UV/LC–MS) and document solution shelf life under your conditions; item-specific stability is not provided.
Solid stability
Keep container well sealed to limit moisture uptake; actual hygroscopicity is unknown. Record receipt date and lot.
Research use note
For research use only. Not for human or veterinary use.
Structure and Identity
Brief overview: This product is listed as the small-molecule Ripisartan. The provided item-specific identifiers are limited; use the CoA/SDS and primary databases for definitive structure confirmation before critical use.
Item-specific identifiers (from Product Data)
Product name: Ripisartan (SKU: R668071)
CAS: 148504-51-2
PubChem CID: 132840
InChIKey: 261047 (as provided; note that typical InChIKeys are 27 characters—verify against CoA/database)
SMILES: Not specified for this item; refer to CoA/Spec Sheet.
Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
Structural features (general/literature context)
Ripisartan is referenced in the literature as a nonpeptide angiotensin II receptor (AT1) antagonist (“sartan” class). Compounds in this class commonly feature a biphenyl scaffold bearing a tetrazole or carboxylate acidic pharmacophore and additional lipophilic/heteroaryl fragments. Confirm Ripisartan’s exact substitution pattern via a primary structural source (CoA, PubChem, patent, or peer‑reviewed article).
2D structural description (general guidance)
Typical sartan chemotypes present: one or more aryl–aryl linkages (biphenyl), an acidic heterocycle (tetrazole), and a polar linker/heteroatom set that modulate affinity and PK. Do not assume these motifs for this specific item without verification.
Synonymy/registries (guidance)
Use the CAS (148504-51-2) and CID (132840) to retrieve canonical SMILES, InChI, and verified InChIKey from trusted databases before method development or analytical ID.
Synthetic Utility
As supplied, Ripisartan is a final small molecule rather than a building block. Nevertheless, understanding its functional motifs can inform derivatization or analytical chemistry.
Functional group landscape (general to sartan-like scaffolds)
Common motifs include an acidic heterocycle (e.g., tetrazole) or carboxylate, multiple aryl rings (often biphenyl), and heteroatom linkers. These features influence ionization, lipophilicity, and chromatography.
Analytical implications
The acidic group can aid negative‑mode ESI‑MS; aromatic systems provide UV chromophores for LC–UV detection. Mixed-mode stationary phases (anion-exchange plus reversed phase) can enhance resolution of related impurities.
Derivatization concepts (advanced; general)
Temporary protection (e.g., as a benzyl ester for carboxylates) or salt formation may be explored for analytical recovery studies, but such chemistry is beyond typical use as a catalog standard.
Retrosynthetic context (literature, general)
Sartan architectures are often assembled via biaryl coupling (Suzuki/Negishi) followed by tetrazole formation from nitriles (azide [3+2] cycloaddition) or by installation of acidic termini and side-chain elaboration. These notes are for educational context and are not instructions for modifying this product.
Target Specificity
Item-specific target information is not provided in the Product Data.
Provided data
Tested targets, binding constants, selectivity profiles, clone/isotype (if antibody), and species reactivity: Not specified for this item; refer to primary literature and CoA/tech sheet if available.
Literature context (general)
Ripisartan is referenced as an angiotensin II AT1 receptor antagonist in the sartan class. Definitive potency (Ki, IC50), selectivity vs AT2, and off-target panels must be confirmed from primary, peer‑reviewed sources before experimental planning.
Guidance
When target specificity is critical, perform an internal orthogonal confirmation (e.g., radioligand displacement plus functional antagonism) using well-characterized comparators.
We use cookies to ensure the website functions properly and, where permitted, to improve your experience. You can manage your preferences at any time in Settings. Learn more in our Cookie Policy.
Shall we send you a message when we have discounts available?
Remind me later
Thank you! Please check your email inbox to confirm.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
